Entries by DrUKM

Profile – BIIB

Biogen Inc., incorporated on April 1, 1997, is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis […]

Profile – GILD

Gilead Sciences, Inc., incorporated on June 22, 1987, is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B […]

Regeneron and Sanofi’s dupilumab shows significant treatment benefit in late-stage dermatitis study

Results from a Phase 3 clinical trial, CHRONOS, evaluating Regeneron Pharmaceuticals (REGN -0.1%) and Sanofi's (SNY -1.4%) DUPIXENT (dupilumab), in combination with topical corticosteroids (TCS), in patients with uncontrolled moderate-to-severe atopic dermatitis (AD) showed a significant treatment benefit compared TCS alone. The data will be presented today at the Annual Meeting of the American Academy […]

Prescriptions jump for EpiPen alternatives

Concerns over the soaring cost of Mylan's (NASDAQ:MYL) EpiPen, plus increased competition, appear to have taken a toll on sales of the brand-name allergy shot. Data from the Athenahealth network shows that prescriptions for EpiPen alternatives have quadrupled since the beginning of 2017. Put another way, the brand-name product's market share has fallen from around […]